Navigation Links
Avastin Added to Chemo Helps Women With Advanced Cancer
Date:5/31/2008

Anti-angiogenesis drug prolonged progression-free survival, study finds

SATURDAY, May 31 (HealthDay News) -- Adding the drug Avastin to chemotherapy lengthened progression-free survival in women with advanced breast cancer, new research shows.

Previous studies have found that adding Avastin (bevacizumab) to the chemotherapy drug Taxol (paclitaxel) in women with advanced breast cancer actually doubled progression-free survival.

Avastin is already approved for use in metastatic colon cancer, non-small cell lung cancer and, recently, in newly diagnosed metastatic breast cancer (in combination with paclitaxel).

"Avastin is an anti-angiogenesis drug [one that inhibits blood supply to the tumor] that appears to have activity across a variety of cancers," Dr. Nancy Davidson, director of the breast cancer program at Johns Hopkins Kimmel Cancer Center in Baltimore and president of the American Society of Clinical Oncology (ASCO), said during a teleconference earlier this month.

"Angiogenesis is clearly a very important process in the tumorogenesis of many malignances, and one of the first agents we've had available to us in the clinic is Avastin, which has demonstrated some efficacy in several genotypes," said study author Dr. David Miles, a medical oncologist at the Mount Vernon Cancer Centre in Middlesex, U.K.

Miles, who is presenting the findings this weekend at the American Society for Clinical Oncology annual meeting in Chicago, spoke at a Saturday news conference.

The current study looked at Avastin added to the chemotherapy agent Taxotere (docetaxel). Taxotere is more commonly used outside the United States, while Taxol is more commonly used in the United States.

This phase III trial involved 736 patients randomized into one of three groups: Taxotere alone, Taxotere plus a high dose (15 mg/kg) of Avastin, or Taxotere plus a low dose of Avastin (7.5 mg/kg). The lower dose of Avastin is the current standard dose for breast cancer treatment, while the higher dose is the standard dose for colon cancer.

After a median follow-up of almost one year, women taking the lower dose of Avastin were 21 percent less likely and those taking the higher dose 28 percent less likely to have a recurrence compared to those receiving chemo alone. More than half (55.2 percent) in the low-dose group and two-thirds (63.3 percent) in the high-dose group saw their tumors shrink, compared to 44.4 percent in the placebo group.

Patients receiving Avastin did have more severe side effects (74 percent to 75 percent versus 67 percent in the chemotherapy-alone group).

Final data on overall survival is not yet available. According to Dr. Eric Weiner, director of the breast oncology center at Dana-Farber Cancer Institute in Boston and moderator of the Saturday news conference, "it is unlikely there will be a survival benefit."

The U.S. Food and Drug Administration tends to approve second and third-line drugs based on progression-free survival and drugs for the first-line setting on survival, Weiner said, adding that he "personally does not understand that approach."

Progression-free survival can be seen as a quality-of-life improvement. "Having the disease under control for longer, as long as the toxicity of treatment is not substantial, is something that is well worth it," Weiner said. "So a drug that can substantially improve profession-free survival is a drug that can at least, in some patients, make their lives that much better while they are dealing with this illness."

More information

The American Society of Clinical Oncology has more information on breast cancer.



SOURCES: May 31, 2008, news conference with Eric Weiner, M.D., director, breast oncology center, Dana-Farber Cancer Institute, Boston; David Miles, M.D., medical oncologist, Mount Vernon Cancer Centre, Middlesex, U.K.; May 6, 2008, teleconference with Nancy Davidson, M.D., director, breast cancer program, Johns Hopkins Kimmel Cancer Center, Baltimore, and president, American Society of Clinical Oncology; May 31, 2008, presentations, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Off-Label Avastin Use for Wet Macular Degeneration
2. FDA OKs Avastin for Advanced Breast Cancer
3. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
6. Taxol with avastin produces noteworthy results
7. FDA Panel Says No to Avastin for Advanced Breast Cancer
8. Welchol(TM) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus
9. IPC The Hospitalist Company Added to Russell 2000 Index
10. Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRALs(R) Live On-air Charity Special Night of Too Many Stars: An Overbooked Concert for Autism Education Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET
11. Turner Investment Partners Added to AHA Diversified Equity Fund
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin Added to Chemo Helps Women With Advanced Cancer
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch ... world headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra ... personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness program ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ... been recognized for adherence to the highest standards of trauma, maternity, cancer and ... the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
Breaking Medicine Technology: